AI주식인사이트AI Stock Insight
B

동구바이오제약

006620KOSDAQ의약품 제조업

57.5 / 100

Reference Date: 2026-07-24

Financial Score25.0 / 40
News Sentiment12.5 / 25
Momentum8.0 / 20
Disclosure12.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Slightly up 4.5% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

DonggubioPharm operates diversified businesses including pharmaceutical manufacturing, new technology investments, marketing services, healthcare services, and pharmaceutical wholesale and consulting. In Q4 2024, its pharmaceutical segment achieved sales of 2,475 billion won, a 15.2% increase compared to the previous year. The company is expanding into new sectors such as biotech investments and medical tourism to enhance growth potential.

Number of Employees

440people

Average Salary

56.5M KRW

Score Calculation Basis

Detailed Financial Score

PER
2.11Industry Average 11.238.0Point

Half of industry avg (excellent)

PBR
0.74Industry Average 0.814.0Point

In line with industry avg

ROE
38.95Industry Average 4.017.0Point

9.7x industry avg (excellent)

Debt Ratio
30.70Industry Average 12.430.0Point

2.5x industry avg (risky)

Trend 2023~20256.0 / 10 points
Revenue Growth Rate
2.0 / 3

Avg ▲6.5% (2-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼20.1% (2-year basis)

ROE Trend
4.0 / 4

Avg ROE 17.3% (improving, 3yr)

Detailed News Sentiment

2 totalPositive 0Neutral 2Negative 0Average Sentiment Score 50

Detailed Momentum

52-week position1.0Point

Near 52w low (16%, downtrend)

Current 3,930Won52-week high 6,09052-week low 3,505
1-month return4.0Point

1m +4.52% (slight rise)

Volume trend3.0Point

Volume flat

Detailed Disclosure

5 totalPositive 1Neutral 4Negative 0
  • Positive주요사항보고서(자기주식취득신탁계약체결결정)2026-07-22
  • Neutral주식등의대량보유상황보고서(일반)2026-07-15
  • Neutral주식등의대량보유상황보고서(일반)2026-07-07
  • Neutral주식등의대량보유상황보고서(일반)2026-06-29
  • Neutral[기재정정]사업보고서 (2025.12)2026-06-25